CN105833148A - 一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物 - Google Patents
一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物 Download PDFInfo
- Publication number
- CN105833148A CN105833148A CN201610300845.1A CN201610300845A CN105833148A CN 105833148 A CN105833148 A CN 105833148A CN 201610300845 A CN201610300845 A CN 201610300845A CN 105833148 A CN105833148 A CN 105833148A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- improving
- blood
- decoction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 171
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 230000036039 immunity Effects 0.000 title claims abstract description 25
- 206010003210 Arteriosclerosis Diseases 0.000 title claims abstract description 17
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims abstract description 17
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 15
- 230000000694 effects Effects 0.000 title abstract description 45
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 claims abstract description 48
- 239000008280 blood Substances 0.000 claims abstract description 48
- 235000000346 sugar Nutrition 0.000 claims abstract description 15
- 238000009835 boiling Methods 0.000 claims description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 210000000582 semen Anatomy 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 239000000706 filtrate Substances 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 24
- 235000014101 wine Nutrition 0.000 claims description 23
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 21
- 230000036541 health Effects 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 238000002386 leaching Methods 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 12
- 206010010774 Constipation Diseases 0.000 claims description 10
- 230000003064 anti-oxidating effect Effects 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 8
- 210000002307 prostate Anatomy 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003390 Chinese drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 208000026455 prostate symptom Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 description 28
- 210000003734 kidney Anatomy 0.000 description 22
- 239000007788 liquid Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 15
- 238000009826 distribution Methods 0.000 description 10
- 230000002708 enhancing effect Effects 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- -1 hydroxypropyl Chemical class 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 235000014510 cooky Nutrition 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 240000005373 Panax quinquefolius Species 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000209051 Saccharum Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000002790 anti-mutagenic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000572565 Alpinia oxyphylla Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 208000025494 Aortic disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 241000269417 Bufo Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 206010065873 Pulmonary fistula Diseases 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JHJUUEHSAZXEEO-UHFFFAOYSA-M sodium;4-dodecylbenzenesulfonate Chemical group [Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1 JHJUUEHSAZXEEO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种提高免疫力、抗动脉硬化、抑制血栓形成、改善记忆力的中药组合物,所述中药组合物包含以下重量份的中药原料:益智仁3‑6份,茯苓9‑15份,黄精10‑30份,枸杞子5‑10份。本发明中药组合物具有改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力、改善***症状、抗疲劳、改善睡眠、降血脂、降血糖,以及抗氧化、抗癌、美容、通便、减肥等功效。
Description
技术领域
本发明涉及中药组合物,具体地说,涉及一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的药食同源组合物。
背景技术
就人一生来说,功能活动经历着发展演变过程。《灵枢·天年》谓:“人生十岁,五脏始定,血气已通,其气在下,故好走。二十岁,血气始盛,肌肉方长,故好趋。三十岁,五脏大定,肌肉坚固,血脉盛满,故好步。四十岁,五脏六腑十二经脉,皆大盛以平定,腠理始疏,荣华颓落,发频斑白,平盛不摇,故好坐。五十岁,肝气始衰,肝叶始薄,胆汁始灭,目始不明。六十岁,心气始衰,苦忧悲,血气懈惰,故好卧。七十岁,脾气虚,皮肤枯。八十岁,肺气衰,魄离,故言善误。九十岁,肾气焦,四脏经脉空虚。百岁,五脏皆虚,神气皆去,形骸独居而终矣。”
从人生百岁轨迹可知,机体一直与致病因素进行着斗争,疾病本身也处于不断发展变化,具有多个不同的发展变化阶段。这些阶段性表明,病是全程的,证是阶段的。证比单纯的症状或病名更能够全面、深刻、确切地揭示疾病变化的本质。病和证之间又存在同病异治或异病同治的关系,所以养生要重视同证异病,异证同病,或同病异治,异病同治的关系。要防治肾阴虚、肾阳虚、肾阴阳两虚、肝肾阴虚、脾肾阳虚、心阴虚、心阳虚、肝气郁结、心肾不交、肺气阴虚等证的发生。这些证揭示着内脏的虚损。所以必须针对这几十种病做防治。
《黄帝内经》早在两千多年前提出了防患于未然的治未病思想,认为医学的最高境界是“圣人不治已病治未病,不治已乱治未乱”(《素问·四气调神大论》)。到了唐代,孙思邈提出“上医医未病之病,中医医欲病之病,下医医已病之病”(《备急千金药方·卷二十七》,将疾病分为“未病”、“欲病”、“已病”三个层次,认为上医是维护健康的养生医学,中医是早期干预的预防医学,下医是针对疾病的治疗医学。
在治法指导下,经历数千年积累,针对防治大量病症的处方已有约千首,但按照现代中药研究对中药划分为广义的中药、可用于保健品的中药、药食两用中药。药食两用中药无疑是上医治未病的养生首选。而已有的约千首处方中,方中全是药食两用中药的配方比例很少,而用全是药食两用中药组成的配方且能涉及防治现在多数人常见的几十种病的处方更是少之又少。
从未病到重病是逐步形成,甚至是长期的过程,现在人认识到对人体生命及功能危害突出的主要病种是:记忆力衰退(痴呆)、动脉硬化、各种血栓等病。
因此,需要研制一种采用既能防治危害人体生命及功能疾病,又能适宜人们天天服用的药食两用中药的养生保健的中药组合物。
发明内容
为了克服现有技术的不足,本发明的发明目的在于提供一种具有改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的药食同源组合物。
本发明的另一发明目的在于提供该药食两用中药组合物的制备方法。
本发明的还一发明目的在于提供该药食两用中药组合物的养生酒。
本发明的还一发明目的在于提供该药食两用中药组合物的养生饮料、食品等。
本发明的再一发明目的在于提供该药食两用中药组合物的应用。
为了实现本发明目的,本发明提供一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物,其特征在于,所述中药组合物包含以下重量份的中药:益智仁3-6份,茯苓9-15份,黄精10-30份,枸杞子5-10份。
上述中药组合物中:
所述重量份可以是μg、mg、g、kg等医药领域公知的重量单位,也可以是其倍数,如1/10、1/100、10倍、100倍等。
其中,优选的是,益智仁4-6份,茯苓12-15份,黄精20-30份,枸杞子5-10份。
进一步地,本发明中药组合物还包括5-9份桑叶,优选为6-9份桑叶。
进一步地,本发明中药组合物还包括10-30份大枣,优选为10-20份大枣。
本发明中药组合物还可以适量添加当归,当归用量为5-15份,优选为8-15份。
本发明还提供了上述中药组合物的制备方法,其包括以下步骤:按照配比称取各中药成分,然后将中药用水浸泡30-60分钟,加水量为中药总重量的5-6倍,然后煮沸,沸后小火沸态,煎煮1-2小时,过滤取滤液,再加入中药总重量5-6倍的水,煎煮1小时,过滤,合并两次滤液,浓缩,即得。
含有上述中药组合物的养生酒,其采用如下步骤制成:按照配比称取各中药成分,然后将中药用水浸泡30-60分钟,加水量为中药总重量的5-6倍,然后煮沸,沸后小火沸态,煎煮1-2小时,过滤取滤液,再加入中药总重量5-6倍的水,煎煮1小时,过滤,合并两次滤液,浓缩至相当于生药重量的1-2倍,即得中药组合物汤剂,然后中药组合物汤剂与酒勾兑,中药组合物汤剂与该酒的体积比为1:(1-5),即成养生酒。也可以勾兑得到一系列不同中药浓度、不同酒精浓度的中药养生酒。
所述酒为优质白酒、米酒、葡萄酒、黄酒、红酒等,其中以优质白酒为佳,尤以浓香型白酒更宜。其度数为小于等于60度,如53度、42度、38度等。
本发明含上述中药组合物的制剂可由该中药组合物单独制成或由该中药组合物和药学上可接受的载体组成。
所述制剂为汤剂、片剂、胶囊剂、丸剂或口服液。所述药学上可接受的载体是指药学领域常规的药物载体,选自填充剂、粘合剂、崩解剂、润滑剂、增溶剂、助悬剂、润湿剂、色素、香精、溶剂、表面活性剂或矫味剂中的一种或几种。
所述填充剂选自淀粉、预胶化淀粉、糊精、葡萄糖、蔗糖、乳糖、乳糖醇、微晶纤维素、甘露醇、山梨醇或木糖醇,优选山梨醇、微晶纤维素、乳糖或预胶化淀粉。
所述崩解剂选自交联羧甲基纤维素钠,交联聚维酮、低取代羟丙基纤维素、羧甲基淀粉钠或淀粉,优选交联聚维酮、低取代羟丙基纤维素或羧甲基淀粉钠。
所述润滑剂选自硬脂酸镁、滑石粉、微粉硅胶、PEG4000、PEG6000、月桂醇硫酸钠,优选硬脂酸镁、滑石粉。
所述粘合剂选自羧甲基纤维素钠、羟丙甲基纤维素、乙基纤维素、聚维酮、淀粉浆、蔗糖、糖粉、胶浆、明胶、聚乙二醇,优选羟丙甲基纤维素、聚维酮。
所述增溶剂选自氢氧化钠、氢氧化钾、碳酸氢钠、甲葡胺、L-赖氨酸、L-精氨酸,优选氢氧化钠、葡甲胺。
所述助悬剂选自微粉硅胶、蜂蜡、纤维素、固态聚乙二醇。
所述润湿剂选自甘油、吐温-80、乙氧基氢化蓖麻油或卵磷脂。
所述溶剂选自乙醇、液态聚乙二醇、异丙醇、吐温-80、甘油、丙二醇或植物油,所述植物油选自大豆油、蓖麻油、花生油、调和油等。
所述表面活性剂选自十二烷基苯磺酸钠、硬脂酸、聚氧乙烯-聚氧丙烯共聚物、脂肪酸山梨坦或聚山梨酯(吐温)等。
所述矫味剂选自阿斯巴甜、蔗糖素、香精、甜菊素、安赛蜜、柠檬酸或糖精钠。
同时,也可以将本发明含上述中药组合物制成各种饮料或食品,便于携带,食用方便。
在用于作为饮料或食品时,本发明中药组合物还可以进一步包括10-30份黑芝麻,9-30份薏苡仁,优选为15-30份黑芝麻,15-30份薏苡仁。
在制备食品时,可以先采用将黑芝麻与薏苡仁共同粉碎至100-200目,再与其他中药原料水煮提取液进行混合,最后按照食品制备工艺制成,比如各种式样的点心、饼干等。
当然,在用于食品加工时,茯苓也可以分两部分添加,一部分茯苓可与黑芝麻、薏苡仁一起粉碎混合加入到食品中。
其中,黑芝麻与薏苡仁以炒熟为佳。
本发明还提供了上述中药组合物在制备治疗或防治机体亚健康态病症产品中的应用。应用具体涉及改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力、改善***症状、抗疲劳、改善睡眠、降血脂、降血糖,以及抗氧化、抗癌、美容、通便、减肥等方面。
本发明中药组合物还可以用于防治肾阴虚、肾阳虚、肾阴阳两虚、肝肾阴虚、脾肾阳虚、心阴虚、心阳虚、肝气郁结、心肾不交等九证和清肺、润燥。
本发明所用药食两用的中药组合物的主要功效、性味归经、功能主治、配伍增效、药理作用分别论述如下:
益智仁:
性味归经:辛,温。归肾、脾经。
功能主治:温肾壮阳,固精缩尿,温脾止泻,摄涎止唾。主要用于肾阳不足,尿频遗尿,遗精滑精,中焦寒冷,脘腹冷疼,吐泻食少,口涎自流。
药理作用:能增强左心房收缩力的活性,具有强心作用。对生殖***的影响,益智仁提取物可抑制***素合成酶的活性。具有抗癌、抗衰老、改善记忆力的作用。
主要保健功效:具有改善记忆力、抗氧化等作用。
茯苓:
性味归经:甘、淡、平。归心、脾、肾经。
功能主治:利水消肿,渗湿,健脾,宁心。主要用于水肿、痰饮、脾虚泄泻、心悸、失眠等。
药理作用:使丙谷转氨酶活力明显降低,防止肝细胞坏死。增强心肌收缩力,有明显利尿作用,提高免疫力,降血糖,抗肿瘤,促进造血。
主要保健功效:具有增强免疫力、降血糖、降血脂、保护肝脏、改善记忆力、提高缺氧耐受力、抗肿瘤等作用。
黄精:
性味归经:甘,平、归脾、肺、肾。
功能主治:润肺滋阴,补脾益气。主要用于肺虚燥咳,痨嗽咳血,精血亏虚,内热消渴,脾虚倦怠,口干食少,大便干燥等。
药理作用:对血脂和动脉硬化的作用:黄***煎液和乙醇提取物能显著降低血清胆固醇及甘油三酸含量,能使主动脉壁膜上的斑块减少和冠状动脉粥样硬化程度减轻。具有降血糖作用,具有抗氧化,提高机体抗自由基的能力,增强免疫力等作用。
主要保健功效:具有降血脂,降血糖,增强免疫力,抗氧化,缓解体力疲劳,保护肝脏等作用。
枸杞子:
性味归经:甘,平。归肝、肾经。
功能主治:补肾益精,养肝明目,润肺止咳。主要用于肾虚腰痛,遗精滑精,阳痿,久不生育,内热消渴,血虚萎黄,目暗不明,头晕目眩,阴虚劳咳,中风头眩,虚烦失眠,风湿痹痛等。
药理作用:具有降血糖、降血脂及保肝、抗脂肪肝作用;具有抗肿瘤作用;具有抗疲劳;抗辐射;耐缺氧;降压;抗突变;抗氧化作用。
主要保健功效:具有增强免疫力、缓解体力疲劳、抗氧化、缓解视疲劳、保护肝脏等作用。
当归:
性味归经:甘,辛,温。归肝、心、脾经。
功能主治:补血活血,调经止痛,润肠通便。主治血虚萎黄,***,经闭痛经,血虚、血滞、血寒诸痛,跌打损伤,风湿痹痛,痈疽疮疡,肠燥便秘等。
药理作用:对心血管***的影响:当归具有降血脂、对主动脉硬化、主动脉病变有一定保护作用。当归中藁本内酯有抑制血小板聚集的作用。当归及其阿魏酸有明显的抗血栓作用。当归多糖具有促进造血功能的作用,增加冠脉血流量的作用,具有增强免疫力功能。还有保肝、抗肿瘤、抗辐射、抗炎、抗氧化、纠正蛋白质代谢紊乱等作用。
主要保健功效:具有增强免疫力,保护肝脏,促进造血,扩张冠状动脉及外周血管。抑制血小板聚集,抗心律失常等作用。
大枣:
性味归经:甘,温。归脾、胃经。
功能主治:补中益气,养血安神,缓和药性。主要用于脾胃虚弱,食少便溏,血虚萎黄,心悸失眠,妇女脏燥,心神不安等。
药理作用:降压作用:大枣内苯甲醇苷,柚配质(糖苷等多种化合物)具有显著降压作用。抗突变作用:大枣水煎液具有抗突变作用。此外大枣尚有一定的抗肿瘤、抗Ⅰ型***反应、抗疲劳、保肝等作用。
主要保健功效:具有增强免疫力、缓解体力疲劳、改善睡眠、保护肝脏、改善营养性贫血等作用。
桑叶:
性味归经:甘,苦,寒。归肺、肝经。
功能主治:疏散风热,清肺润燥,平抑肝阳,清肝明目,凉血止血。主要用于风热感冒,温病初起,肺热咳嗽、燥热咳嗽,肝阳上亢,目赤昏花,血热咳吐衄血等证。
药理作用:降血糖作用:桑叶总多糖有显著的降血糖作用,并可提高糖尿病小鼠的耐糖能力,增加肝糖元含量而降低肝葡萄糖,提高正常大鼠血中胰岛素水平。此外,一些无机元素对其降血糖机制也起一定作用。对血管***的影响:桑叶中所含的芸香苷、槲皮素能增加离体及在位蛙心的收缩力及心输出量,并减慢心率。芸香苷使蟾蜍下肢及兔耳血管收缩;槲皮素可扩张冠状血管。芸香苷及槲皮素能保持毛细血管正常的抵抗力,减少血管通透性,可使因脆性增加而出血的毛细血管恢复正常的弹性。芸香苷及槲皮素有一定的降压作用。
主要保健功效:具有降血糖,增强免疫力,通便,祛黄褐斑等作用。
黑芝麻:
性味归经:甘,平。归肝、肾、大肠经。
功能主治:补益精血,润燥滑肠。主要用于须发早白,头晕眼花,妇女产后乳少,风痹,血虚津枯,肠燥便秘等。西医诊为神经衰弱、高血压、习惯性便秘等,属于肝肾不足,精血亏虚者。
药理作用:抗衰老作用:黑芝麻可使衰老现象推迟发生,肝脏和睾丸中脂褐质水平降低,而血浆中维生素E含量增高。降胆固醇的作用:所含亚油酸可降低血中胆固醇含量。
主要保健功效:具有降血糖、降血脂、润肠通便等作用。
薏苡仁:
性味归经:甘,淡,凉。归脾、胃、肺经。
功能主治:利水消肿,渗湿,健脾,除痹,清热排脓。主要用于水肿、小便不利、脚气、脾虚泄泻、湿痹拘挛、肺瘘、肺痈、肠痈、淋浊、白带等。
药理作用:对中枢神经***的作用:薏苡仁有镇静、镇痛作用。
抗癌作用:薏苡仁醇提物腹腔注射对小鼠艾氏腹水癌有抑制,能明显延长动物的生存作用。
此外薏苡仁还有诱发***、降温与降热、抑制胰蛋白酶、抗菌、抑制多突触反射、降血糖、降血钙、增强免疫功能的作用。
主要保健功效:具有增强免疫力,降血糖,祛黄褐斑等作用。
本发明提高免疫力、抗动脉硬化、抑制血栓形成、改善记忆力的药食同源组合物,具有以下有益效果:
1.本发明中药组合物选取药食两用中药原料为基础,经过试验研究,确定了以特定用量的益智仁、茯苓、黄精、枸杞子为配伍基础,达到协同配伍增效的功能,取得提高免疫力、抗动脉硬化、抑制血栓形成、改善记忆力的功效;同时并进一步辅佐加入桑叶、大枣、当归,以及黑芝麻及薏苡仁,可以进一步提升或拓宽组合物的功效。
2.本发明中药组合物可用于防治肾阴虚、肾阳虚、肾阴阳两虚、肝肾阴虚、脾肾阳虚、心阴虚、心阳虚、肝气郁结、心肾不交等九证和清肺、润燥。
3.本发明药食两用中药组合物均归肾经,都有补肾功效。
4.本发明的中药组合物具有补脑益髓作用,可以改善脑功能。
5.老年肾上腺萎缩对ACTH促肾上腺皮质(激)素反应降低,尿中酮皮质类固醇排量比青壮年低,内分泌功能减退是衰老原因之一。肾藏精,精生髓,脑为髓海。故肾精充盛,则脑髓充足而肢体行动灵活,耳目聪敏,所谓“髓海有余,则轻劲有力”精盈髓充,则脑自健,脑健则生智慧,强意志,利耳目,轻身延年。故防治老年性痴呆多从补肾益髓入手,否则失智,则痴呆。
6.本发明中药组合物具有改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力、改善***症状、抗疲劳、改善睡眠、降血脂、降血糖,以及抗氧化、抗癌、美容、通便、减肥等方面功效。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1:中药组合物汤剂
1、组成:益智仁40g,茯苓150g,黄精250g,枸杞子100g,当归100g,大枣200g(合计840g)。
2、制备方法:按照配比称取各中药成分,然后将中药用水浸泡40分钟,加水量为中药总重量的6倍(即5040g),然后煮沸,沸后小火沸态,煎煮2小时,过滤取滤液,再加入中药总重量6倍的水(即5040g),沸后小火沸态,煎煮1小时,过滤,合并两次滤液,减压浓缩至840ml,即得中药组合物汤剂(每ml含生药1g)。
实施例2:中药组合物汤剂
1、组成:益智仁50g,茯苓100g,黄精200g,枸杞子80g,当归120g,大枣250g(合计800g)。
2、制备方法:按照配比称取各中药成分,然后将中药用水浸泡40分钟,加水量为中药总重量的5倍(即4000g),然后煮沸,沸后小火沸态,煎煮2小时,过滤取滤液,再加入中药总重量5倍的水(即4000g),沸后小火沸态,煎煮1小时,过滤,合并两次滤液,减压浓缩至1600ml,即得中药组合物汤剂(每ml含生药0.5g)。
实施例3:中药组合物汤剂
1、组成:益智仁60g,茯苓120g,黄精150g,枸杞子60g(合计390g)。
2、制备方法:按照配比称取各中药成分,然后将中药用水浸泡40分钟,加水量为中药总重量的5倍(即1950g),然后煮沸,沸后小火沸态,煎煮2小时,过滤取滤液,再加入中药总重量5倍的水(即1950g),沸后小火沸态,煎煮1小时,过滤,合并两次滤液,减压浓缩至700ml,即得中药组合物汤剂(每ml含生药0.55g)。
实施例4:中药组合物汤剂
1、组成:益智仁30g,茯苓100g,黄精250g,枸杞子100g,桑叶100g(合计580g)。
2、制备方法:按照配比称取各中药成分,然后将中药用水浸泡40分钟,加水量为中药总重量的5倍(即2900g),然后煮沸,沸后小火沸态,煎煮2小时,过滤取滤液,再加入中药总重量5倍的水(即2900g),沸后小火沸态,煎煮1小时,过滤,合并两次滤液,减压浓缩至600ml,即得中药组合物汤剂(每ml含生药0.96g)。
实施例5:养生酒剂制备
1、组成:益智仁60g,茯苓90g,黄精150g,枸杞子60g,当归80g,大枣150g,桑叶60g(合计650g)。
2、制备方法:
按照配比称取各中药成分,然后将中药用水浸泡40分钟,加水量为中药总重量的5倍,然后煮沸,沸后小火沸态,煎煮2小时,过滤取滤液,再加入中药总重量6倍的水,沸后小火沸态,煎煮1小时,过滤,合并两次滤液,减压浓缩至1300ml,即得中药组合物汤剂(每ml含生药0.50g)。
将中药组合物汤剂与53度白酒,中药组合物体积与该白酒体积之比可为1:1,即成养生酒,每ml含0.25g生药。
实施例6:养生酒剂制备
1、组成:益智仁30g,茯苓150g,黄精220g,枸杞子100g,当归100g,大枣220g(合计820g)。
2、制备方法:
按照实施例2的方法制备中药组合物汤剂。
将中药组合物汤剂与39度浓香型白酒勾兑,中药组合物体积与该白酒体积之比可为1:1,即成养生酒,每ml含0.25g生药。
实施例7:养生酒剂制备
1、组成:益智仁40g,茯苓120g,黄精250g,枸杞子80g,桑叶90g,大枣200g(合计780g)。
2、制备方法:
按照实施例2的方法制备中药组合物汤剂。
将中药组合物汤剂与39度浓香型白酒勾兑,中药组合物体积与该白酒体积之比可为1:1,即成养生酒,每ml含0.25g生药。
实施例8:片剂(下列剂量为10剂用量)
1、组成:益智仁50g,茯苓150g,黄精250g,枸杞子100g,当归100g,大枣200g,桑叶80g(合计920g)。
2、制备方法:将上述中药加水浸泡30分钟,水面高于原料中药,加水量为总药量的6倍,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤取滤液,再加入总药量5倍的水,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤并合并两次滤液,经减压浓缩(压力0.06MPa,温度65℃)至干膏,粉碎,即得230g中药组合物(收率为25%,每g含生药4g)。
3、片剂:100g中药组合物与50g淀粉混合,过60目筛,制粒,干燥,再加4g硬脂酸镁,压片,即得片剂。
实施例9:胶囊
1、组成:益智仁40g,茯苓100g,黄精300g,枸杞子50g,当归80g,大枣150g,桑叶50g(合计770g)。
2、制备方法:将上述中药加水浸泡50分钟,水面高于原料中药,加水量为总药量的5倍,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤取滤液,再加入总药量5倍的水,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤并合并两次滤液,经减压浓缩(压力0.06MPa,温度65℃)至干膏,粉碎,即得200.2g中药组合物(收率为26%,每g含生药3.85g)。
3、胶囊:中药组合物过300目筛,称取中药组合物100g,加入总重量2%的硬脂酸镁,分装入胶囊,即可。
实施例10:丸剂
1、组成:益智仁60g,茯苓150g,黄精250g,枸杞子80g,当归100g,大枣100g,黑芝麻200g,薏苡仁100g(合计1040g)。
2、制备方法:将上述中药加水浸泡60分钟,水面高于原料中药,加水量为总药量的8倍,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤取滤液,再加入总药量6倍的水,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤并合并两次滤液,经减压浓缩(压力0.06MPa,温度65℃)至干膏。
3、丸剂:水泛为丸,包衣,即可。
实施例11:口服液
1、组成:益智仁40g,茯苓125g,黄精240g,枸杞子100g,当归80g,大枣250g,桑叶90g(合计925g)。
2、制备方法:将上述中药加水浸泡45分钟,水面高于原料中药,加水量为总药量的8倍,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤取滤液,再加入总药量6倍的水,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤合并滤液,浓缩至相对密度为1.17(70℃)的清膏,即得259g中药组合物(收率为28%,每g含生药3.57g)。
3、口服液:中药组合物100g加乙醇,使含醇量达65%,用氢氧化钠调节pH至6.8,静置36小时,滤过,向滤液中加入乙醇,使含醇量达75%,静置24小时,滤过,将滤液回收乙醇至无醇味,加热微沸15分钟,搅匀,加水至1000ml,搅匀,滤过,灌封,即得口服液(每ml含0.333g生药)。
实施例12:饼干
1、组成:益智仁50g,茯苓120g,黄精150g,枸杞子60g,当归120g,大枣180g,桑叶80g,黑芝麻300g,薏苡仁200g(合计1260g)。
2、制备方法:将除黑芝麻和薏苡仁之外的中药加水浸泡45分钟,水面高于原料中药,加水量为总药量的8倍,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤取滤液,再加入总药量6倍的水,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤合并滤液;
然后将黑芝麻300g和薏苡仁200g共同粉碎至100目,加入合并滤液,再加入1000g低筋面粉、黄油600g、砂糖500g、鸡蛋250g,按照饼干制备工艺烘焙而成。
实施例13:饼干
1、组成:益智仁40g,茯苓100g,黄精120g,枸杞子80g,当归100g,大枣150g,桑叶70g,黑芝麻250g,薏苡仁250g(合计1160g)。
2、制备方法:将除黑芝麻、薏苡仁和茯苓30g之外的中药加水浸泡45分钟,水面高于原料中药,加水量为总药量的8倍,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤取滤液,再加入总药量6倍的水,沸后小火沸态,维持液面高于原料中药高度,煎煮两小时,过滤合并滤液;
然后将茯苓30g、黑芝麻250g和薏苡仁250g共同粉碎至100目,加入合并滤液,再加入1500g低筋面粉、黄油800g、砂糖600g、鸡蛋200g,按照饼干制备工艺烘焙而成。
以下实验例,是本发明产品在临床进行实验时进行的。
实验例1
通过对如下试服用人员进行试验,试验结果如下:
1)苏XX,男,79岁,患主动脉夹层B型动脉硬化较重,发展较快,CTA证实,血管中钙化点密集。服用实施例1汤剂一年,再做CTA证实这一年血管状况无再恶化,自觉身体比过去较舒适,B型夹层较稳定。
2)赵XX,男,65岁,右手端水碗抖幅在1公分左右,服实施例1汤剂一个月后,有时不抖了,有时抖其振幅也只有0.5公分。
3)周XX,男,55岁,双掌短肌位肤色呈暗紫色,血液循环差不畅。服实施例2汤剂一个月,双手掌短肌位肤色呈正常肤色,无暗紫色。
4)李XX,男,70岁,右手写字手抖,写出字其体见抖样。服实施例1汤剂一个月,能以正常速度写出不抖字体的字。
5)纪XX,男,56岁,右手伸直,手背向上抬手,不自觉的出现抖幅2毫米,服实施例3汤剂一个月,再以同姿态伸手,不见抖了。
6)李XX,女,60岁,血瘀血虚面色委黄,虚不受补,全身乏力,服实施例1汤剂三周后自觉精气神足,面色明显改善。
7)何XX,男,65岁,倦思,自觉头脑不清晰,记忆力下降很明显,五天前的事都记不起来,服实施例4汤剂二周后,自觉思维较灵活,也辛勤思考问题,对五天前的事能较清楚回忆,记得起来。
8)卢XX,女,55岁,睡眠很差,一宿只睡着4小时,记忆力很差,服实施例1汤剂一周,则每晚能睡着6小时以上,记忆力有明显改善。
9)张XX,男,56,男性更年期综合征,无晨勃,服实施例1汤剂20天,出现晨勃,服30天,每天有晨勃。
10)高XX,男,78岁,二十年来,舌下左右两大血管呈紫黑色,下嘴唇呈暗紫色,服实施例1汤剂30天,舌下左右两大血管变为灰色(正常色),下嘴唇变为粉红色。
11)李XX,男,75岁,痰湿型体质较日常上楼梯时,腿觉似灌铅,上三层楼则出现大喘气,服实施例1汤剂四周,自觉上楼梯不觉吃力,也不出现大喘气。
12)高XX,男,73岁,自觉气血不畅,身重乏力,走路每步只能迈出30公分,服实施例1汤剂四周,自觉身劲有力,走路每步能迈出60公分。
13)王XX,女,40岁,经常出现感冒,免疫力较低,常感在疲劳态。服实施例1汤剂四周,半年来未出现感冒,自觉不疲劳,精气神较之前也足了。
14)王XX,男,68岁,***增生pSA标远大于10,每宿起尿3-4次,睡眠差,总感觉***位在受刺激态,服实施例1汤剂三周后,继续服,每夜只起床尿一次,***受刺激非常不明显了。
实验例2
在北京艺宫酒店某产品发布会上和某老干局餐厅,经30位参会人士以及60位老干部服用实施例5养生酒,皆感到不上头、不干喉、顺口顺喉、心情愉悦、轻身有力、精气神足、无任何副作用。
本发明药食同源中药组合物已有抗动脉硬化,抑制血栓形成等功效。其酒剂则能进一步增效。人体适量摄入酒精可增加血液中高密度脂蛋白,减少低密度脂蛋白。低密度脂蛋白是动脉粥样硬化斑块中胆固醇的主要供应者。高密度脂蛋白与低密度脂蛋白竞争血管壁中平滑肌细胞浆膜上的受体,从而抑制血管壁平滑肌细胞社区和蓄积低密度脂蛋白,进而预防动脉粥样硬化斑块的形成。酒作为药物的载体,会进一步提高本中药组合物的生物利用度。
实验例3
本发明药食两用中药组合物(以实施例1六味药食两用中药组合物)经现代中医量子共振仪(QRS量子共振检测仪河北纳百川科技开发有限公司)测量,对人体29项补益数据如下,无任何副作用,养生防病指数非常理想。
人体一般情况下正常值判定方法:
亚健康(0至+8),健康正常值(+9至+21),疾病状态(0至-21)。
结果显示,QRS量子检测出本发明中药组合物的养生防病康复指标很优秀。尤其提高免疫功能、补肾、缓解极度疲劳、抑制血栓形成、改善血液循环、抗动脉硬化等方面的功能更为显著。并具有难能可贵的改善记忆力的好功能;人体实验,效果曲线与量子检测特性吻合或相近。
服用本发明药食两用中药组合物(用于补充以上量子数据)可帮助已病者向亚健康转变,可使亚健康人的量子数据变为健康人的量子数据,可使健康人的量子数据变为更健康人的量子数据。因此达到养生、预防和康复的效果。
综上所述及临床实验证实,本发明的中药组合物可用于防治肾阴虚、肾阳虚、肾阴阳两虚、肝肾阴虚、脾肾阳虚、心阴虚、心阳虚、肝气郁结、心肾不交等九证。具有改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力、改善***症状、抗疲劳、改善睡眠、降血脂、降血糖,以及抗氧化、抗癌、美容、通便、减肥等方面功效。
虽然,上文中已经用一般性说明、具体实施方式及试验,对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.一种提高免疫力、抗动脉硬化、抑制血栓形成、改善记忆力的中药组合物,其特征在于,所述中药组合物包含以下重量份的中药原料:益智仁3-6份,茯苓9-15份,黄精10-30份,枸杞子5-10份。
2.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物包含以下重量份的中药原料:益智仁4-6份,茯苓12-15份,黄精20-30份,枸杞子5-10份。
3.根据权利要求1或2所述的中药组合物,其特征在于,还包括5-9份桑叶。
4.根据权利要求1-3任意一项所述的中药组合物,其特征在于,还包括10-30份大枣。
5.根据权利要求1-4任意一项所述的中药组合物,其特征在于,还包括5-15份当归。
6.根据权利要求1-5任意一项所述的中药组合物,其特征在于,还包括10-30份黑芝麻,9-30份薏苡仁。
7.含有权利要求1-5任意一项所述中药组合物的养生酒,其特征在于,采用如下步骤制成:按照配比称取各中药成分,然后将中药用水浸泡30-60分钟,加水量为中药总重量的5-6倍,然后煮沸,沸后小火沸态,煎煮1-2小时,过滤取滤液,再加入中药总重量5-6倍的水,煎煮1小时,过滤,合并两次滤液,浓缩至相当于生药重量的1-2倍,即得中药组合物汤剂,然后中药组合物汤剂与酒勾兑,中药组合物汤剂与该酒的体积比为1:(1-5),即成养生酒。
8.含权利要求1-6任一项所述中药组合物的制剂,由该中药组合物单独制成或由该中药组合物和药学上可接受的载体组成。
9.权利要求1-6任一项所述中药组合物、权利要求7所述养生酒、权利要求8所述的制剂在制备治疗或防治机体亚健康态病症产品中的应用。
10.根据权利要求9所述的应用,其特征在于,所述应用为改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力、改善***症状、抗疲劳、改善睡眠、降血脂、降血糖、抗氧化、抗癌、美容、通便。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610300845.1A CN105833148A (zh) | 2016-05-09 | 2016-05-09 | 一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610300845.1A CN105833148A (zh) | 2016-05-09 | 2016-05-09 | 一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105833148A true CN105833148A (zh) | 2016-08-10 |
Family
ID=56591210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610300845.1A Pending CN105833148A (zh) | 2016-05-09 | 2016-05-09 | 一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105833148A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106974285A (zh) * | 2017-03-31 | 2017-07-25 | 江苏康缘药业股份有限公司 | 一种中药组合物及其应用 |
CN106995772A (zh) * | 2017-05-18 | 2017-08-01 | 江苏洋河酒厂股份有限公司 | 一种增强免疫力的保健酒 |
CN109757582A (zh) * | 2018-12-29 | 2019-05-17 | 江苏鹤莱科技有限公司 | 改善良性***增生症状的营养食品配方 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1240591A (zh) * | 1998-06-30 | 2000-01-12 | 肖树恩 | 一种消渴糖 |
CN1565249A (zh) * | 2003-07-05 | 2005-01-19 | 张锐 | 一种烹调用中草药营养调味品 |
CN103316144A (zh) * | 2013-07-08 | 2013-09-25 | 宋述伋 | 一种补益气血、养阴益阳、提高免疫力、抗疲劳、抑制血栓形成的中药组合物 |
-
2016
- 2016-05-09 CN CN201610300845.1A patent/CN105833148A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1240591A (zh) * | 1998-06-30 | 2000-01-12 | 肖树恩 | 一种消渴糖 |
CN1565249A (zh) * | 2003-07-05 | 2005-01-19 | 张锐 | 一种烹调用中草药营养调味品 |
CN103316144A (zh) * | 2013-07-08 | 2013-09-25 | 宋述伋 | 一种补益气血、养阴益阳、提高免疫力、抗疲劳、抑制血栓形成的中药组合物 |
Non-Patent Citations (1)
Title |
---|
杨力: "《杨力解读中华养生智慧》", 31 January 2012, 科学技术文献出版社 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106974285A (zh) * | 2017-03-31 | 2017-07-25 | 江苏康缘药业股份有限公司 | 一种中药组合物及其应用 |
CN106974285B (zh) * | 2017-03-31 | 2020-12-08 | 江苏康缘药业股份有限公司 | 一种中药组合物及其应用 |
CN106995772A (zh) * | 2017-05-18 | 2017-08-01 | 江苏洋河酒厂股份有限公司 | 一种增强免疫力的保健酒 |
CN109757582A (zh) * | 2018-12-29 | 2019-05-17 | 江苏鹤莱科技有限公司 | 改善良性***增生症状的营养食品配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102836379B (zh) | 一种降脂解酒的中药复方制剂及其制备方法与应用 | |
CN103520621B (zh) | 一种治疗老年性白内障的中药组合物及其制备方法 | |
CN103860969A (zh) | 一种增肥的中药 | |
CN103405728B (zh) | 一种治疗更年期综合症的中药组合物及其制备方法 | |
CN105031394A (zh) | 一种中药组合物及其制备的保健药酒 | |
CN105833148A (zh) | 一种改善记忆力、抗动脉硬化、抑制血栓形成、提高免疫力的中药组合物 | |
CN101468150B (zh) | 补肾润发的中药组合物、制剂及其制备方法 | |
CN103989970B (zh) | 一种治疗高血压的中药组合物 | |
CN103977206B (zh) | 改善肠胃消化***功能的中药制剂及其生产方法 | |
CN102940730A (zh) | 治疗高血压的中药 | |
CN105232911A (zh) | 一种中药组合物 | |
CN106177477A (zh) | 一种用于降血糖、降血脂和降血压的保健组合物 | |
CN102512591B (zh) | 一种具有减肥降糖降脂作用的组合物 | |
CN101099775B (zh) | 一种治疗心脑血管疾病的药物 | |
CN103316144B (zh) | 一种补益气血、养阴益阳、提高免疫力、抗疲劳、抑制血栓形成的中药组合物 | |
CN104740054B (zh) | 一种防治心肌缺血的药物组合物及其制备方法和用途 | |
CN104432386B (zh) | 一种防治腰膝酸软、筋骨无力的桑寄生口服液及其制备方法 | |
CN103463456A (zh) | 一种中药组合物及其制备方法 | |
CN105560911B (zh) | 一种治疗高血压的中药及其制备方法 | |
CN109718304A (zh) | 改善人体心脑血管功能微循环及预防血栓的中药组合物 | |
CN104906399A (zh) | 一种治疗心脏病的中药丸剂及其制备方法 | |
CN104524479A (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN109718305A (zh) | 改善人体气血功能提高耐缺氧延缓衰老的中药组合物 | |
CN103495101B (zh) | 一种用于治疗胃痛的中药组合物 | |
CN106110089A (zh) | 一种治疗焦虑、失眠的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160810 |